| Accession |
PRJCA018628 |
| Title |
SHR-1210-III-306-PD-1 antibody SHR 1210 combined with paclitaxel and cisplatin control placebo combined with paclitaxel and cisplatin in first-line treatment of advanced esophageal cancer |
| Relevance |
Medical |
| Data types |
clinical data,biomarker data,etc.
|
| Organisms |
Homo sapiens
|
| Description |
To evaluate the safety and tolerability of SHR-1210 in subjects with advanced solid tumors after failure of standard antitumor therapy. |
| Sample scope |
Multiisolate |
| Release date |
2023-07-27 |
| Grants |
| Agency |
program |
Grant ID |
Grant title |
| NA
|
NA
|
NA
|
NA
|
|
|
| Submitter |
luchongyang
chongyang
lu (chongyang.lu@hengrui.com)
|
| Organization |
Jiangsu Hengrui Pharmaceutical Co. LTD |
| Submission date |
2023-07-27 |
